601607 上海醫藥
按盤價 
17.930 -0.300 (-1.646%) | 2025/06 - 中期 人民幣(K¥) | 與去年同期 比較 | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | ||
| 營業總收入 | 141,592,783 | 1.56% | 275,250,935 | 260,295,089 | 231,981,300 | 215,824,259 | |
| 減：營業總成本 | 137,611,881 | 2.02% | 267,676,307 | 253,008,864 | 224,907,251 | 209,641,475 | |
| 其中:營業成本 | 126,660,061 | 2.77% | 244,619,261 | 228,966,947 | 201,494,923 | 187,281,149 | |
| 財務費用 | 749,775 | 6.21% | 1,480,912 | 1,485,758 | 1,313,192 | 1,245,369 | |
| 資產減值損失 | (410,078) | 1,022.70% | (614,374) | (561,277) | (331,471) | (140,441) | |
| 公允價值變動收益 | 75,752 | -33.72% | 203,854 | 404,731 | 218,738 | (206,004) | |
| 投資收益 | 3,257,333 | 1,222.17% | 380,427 | (68,123) | 533,117 | 1,811,394 | |
| 其中：對聯營企業和合營企業的投資收益 | 380,664 | 4.12% | 521,909 | 129,329 | 526,743 | 789,596 | |
| 營業利潤 | 6,833,620 | 41.46% | 8,140,713 | 7,667,235 | 9,014,650 | 8,205,486 | |
| 利潤總額 | 6,820,821 | 41.45% | 8,020,007 | 7,054,297 | 8,808,353 | 8,143,815 | |
| 減：所得稅費用 | 1,826,037 | 49.11% | 2,149,995 | 1,887,726 | 1,816,339 | 1,869,245 | |
| 淨利潤 | 4,994,784 | 38.85% | 5,870,011 | 5,166,570 | 6,992,015 | 6,274,569 | |
| 減：非控股權益 | 535,919 | -18.24% | 1,317,483 | 1,398,571 | 1,374,863 | 1,181,102 | |
| 股東淨利潤 | 4,458,865 | 51.56% | 4,552,528 | 3,768,000 | 5,617,152 | 5,093,467 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 1.200 | 51.90% | 1.230 | 1.020 | 1.610 | 1.790 | |
| 每股派息 (元) * | -- | -- | 0.370 | 0.410 | 0.610 | 0.420 | |
| 每股淨資產 (元) * | 20.250 | 7.15% | 19.330 | 18.500 | 18.137 | 17.367 | |
| 審計意見 # | -- | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | 标准无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 即時報價更新時間為 19/09/2025 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
